{
    "title": "AstraZeneca diabetes drug combination faces delay after FDA rebuff",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-3275430/AstraZeneca-diabetes-drug-combination-faces-delay-FDA-rebuff.html",
    "date": "2015-10-16",
    "keywords": [
        "drug",
        "combination",
        "move",
        "delay",
        "october",
        "launch",
        "fda",
        "saxagliptin",
        "astrazeneca",
        "company",
        "trial",
        "type",
        "farxiga",
        "rebuff",
        "gmt",
        "email",
        "ben",
        "hirschlerlondon",
        "health",
        "blow",
        "plank",
        "friday",
        "response",
        "letter",
        "food",
        "administration",
        "approval",
        "wait",
        "blockbuster",
        "cocktail",
        "bank",
        "analyst",
        "richard",
        "lack",
        "formulation",
        "safety",
        "efficacy",
        "bestcase",
        "scenario",
        "year",
        "defence",
        "takeover",
        "attempt",
        "pfizer",
        "dapagliflozin",
        "revenue",
        "morning",
        "percent",
        "rise",
        "sector",
        "information",
        "component",
        "mix",
        "treatment",
        "brand",
        "status",
        "onglyza",
        "half",
        "milliononglyza",
        "dppiv",
        "inhibitor",
        "januviafarxiga",
        "class",
        "sglt2",
        "excitement",
        "month",
        "jardiance",
        "risk",
        "heart",
        "attack",
        "stroke",
        "editing",
        "jane",
        "merriman",
        "croft"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}